{"id":832835,"date":"2025-04-02T08:02:07","date_gmt":"2025-04-02T12:02:07","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/syndax-announces-participation-at-the-stifel-2025-virtual-targeted-oncology-forum\/"},"modified":"2025-04-02T08:02:07","modified_gmt":"2025-04-02T12:02:07","slug":"syndax-announces-participation-at-the-stifel-2025-virtual-targeted-oncology-forum","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/syndax-announces-participation-at-the-stifel-2025-virtual-targeted-oncology-forum\/","title":{"rendered":"Syndax Announces Participation at the Stifel 2025 Virtual Targeted Oncology Forum"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">NEW YORK, April  02, 2025  (GLOBE NEWSWIRE) &#8212; Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, as well as members of the Syndax management team, will participate in a fireside chat at the Stifel 2025 Virtual Targeted Oncology Forum on Wednesday, April 9, 2025, at 10:30 a.m. ET.<\/p>\n<p align=\"justify\">A live webcast of the fireside chat will be available in the Investor section of the Company&#8217;s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=pD_NQf0ITd8YBZ7e0IZMasiJy8ZXFBdQA2wivjxiAzHKu2-YFWjxELF7BlDYZq_93jmefn0MoRhBj7nIHtj0lA==\" rel=\"nofollow\" target=\"_blank\">www.syndax.com<\/a>, where a replay will also be available for a limited time.<\/p>\n<p align=\"justify\">\n        <strong>About Syndax<\/strong>\n      <\/p>\n<p align=\"justify\">Syndax Pharmaceuticals\u00a0is a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company&#8217;s pipeline include Revuforj<sup>\u00ae<\/sup> (revumenib), an FDA-approved menin inhibitor, and Niktimvo\u2122 (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=pD_NQf0ITd8YBZ7e0IZMardC6CHMzXGFPvi7kouR0wNCuR4PfXvyJwqvYrOzLTGg7gwwOZlwcx_uqGeAhEUc4w==\" rel=\"nofollow\" target=\"_blank\">www.syndax.com<\/a> or follow the Company on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Jx2657scQkTuCmcGbU9-1YeAWPIbOmMIEINvpRpDVwU9IhtNYu2nFqIHi-n8-hQVvGunjLdEJCDzRcVvaTP2fw==\" rel=\"nofollow\" target=\"_blank\">X<\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=GxPWwWLq__Q5phsnLBUcF4e9R-OOEFtCZiYtB3QjOuCUEMY47OfeRNc-cdxnr4gxr2Qm-S-C3HOYbh1aFQg6CjP5HaROtfYEOnhQaETuq3_akudusiZ356hyjcon6JKA\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>.<\/p>\n<p>\n        <strong>Syndax Contacts<\/strong>\n      <\/p>\n<p>Sharon Klahre<br \/>Syndax Pharmaceuticals, Inc.<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=RKOLrQDl1Er3-l1ov8CYdzwLLs1nwaP25xSU5JFdiTIiwahErhPAAe6GhUUZvK8Bas1dWwKciujLFfRbeqaxNE2NJwmYehojFoZ1JS7bEQw=\" rel=\"nofollow\" target=\"_blank\">sklahre@syndax.com<\/a><br \/>Tel 781.684.9827<\/p>\n<p>SNDX-G<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNDI3OCM2ODQzOTE5IzIwMDQ4Mzk=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NjkzZWU5ZjYtZjMzMC00NTMwLTgzZmYtNWM3YTM1MDBmYzdlLTEwMTY0MTItMjAyNS0wNC0wMi1lbg==\/tiny\/Syndax-Pharmaceuticals-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK, April 02, 2025 (GLOBE NEWSWIRE) &#8212; Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, as well as members of the Syndax management team, will participate in a fireside chat at the Stifel 2025 Virtual Targeted Oncology Forum on Wednesday, April 9, 2025, at 10:30 a.m. ET. A live webcast of the fireside chat will be available in the Investor section of the Company&#8217;s website at www.syndax.com, where a replay will also be available for a limited time. About Syndax Syndax Pharmaceuticals\u00a0is a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company&#8217;s pipeline include Revuforj\u00ae (revumenib), &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/syndax-announces-participation-at-the-stifel-2025-virtual-targeted-oncology-forum\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Syndax Announces Participation at the Stifel 2025 Virtual Targeted Oncology Forum&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-832835","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Syndax Announces Participation at the Stifel 2025 Virtual Targeted Oncology Forum - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/syndax-announces-participation-at-the-stifel-2025-virtual-targeted-oncology-forum\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Syndax Announces Participation at the Stifel 2025 Virtual Targeted Oncology Forum - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, April 02, 2025 (GLOBE NEWSWIRE) &#8212; Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, as well as members of the Syndax management team, will participate in a fireside chat at the Stifel 2025 Virtual Targeted Oncology Forum on Wednesday, April 9, 2025, at 10:30 a.m. ET. A live webcast of the fireside chat will be available in the Investor section of the Company&#8217;s website at www.syndax.com, where a replay will also be available for a limited time. About Syndax Syndax Pharmaceuticals\u00a0is a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company&#8217;s pipeline include Revuforj\u00ae (revumenib), &hellip; Continue reading &quot;Syndax Announces Participation at the Stifel 2025 Virtual Targeted Oncology Forum&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/syndax-announces-participation-at-the-stifel-2025-virtual-targeted-oncology-forum\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-02T12:02:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNDI3OCM2ODQzOTE5IzIwMDQ4Mzk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/syndax-announces-participation-at-the-stifel-2025-virtual-targeted-oncology-forum\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/syndax-announces-participation-at-the-stifel-2025-virtual-targeted-oncology-forum\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Syndax Announces Participation at the Stifel 2025 Virtual Targeted Oncology Forum\",\"datePublished\":\"2025-04-02T12:02:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/syndax-announces-participation-at-the-stifel-2025-virtual-targeted-oncology-forum\\\/\"},\"wordCount\":204,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/syndax-announces-participation-at-the-stifel-2025-virtual-targeted-oncology-forum\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxNDI3OCM2ODQzOTE5IzIwMDQ4Mzk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/syndax-announces-participation-at-the-stifel-2025-virtual-targeted-oncology-forum\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/syndax-announces-participation-at-the-stifel-2025-virtual-targeted-oncology-forum\\\/\",\"name\":\"Syndax Announces Participation at the Stifel 2025 Virtual Targeted Oncology Forum - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/syndax-announces-participation-at-the-stifel-2025-virtual-targeted-oncology-forum\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/syndax-announces-participation-at-the-stifel-2025-virtual-targeted-oncology-forum\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxNDI3OCM2ODQzOTE5IzIwMDQ4Mzk=\",\"datePublished\":\"2025-04-02T12:02:07+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/syndax-announces-participation-at-the-stifel-2025-virtual-targeted-oncology-forum\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/syndax-announces-participation-at-the-stifel-2025-virtual-targeted-oncology-forum\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/syndax-announces-participation-at-the-stifel-2025-virtual-targeted-oncology-forum\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxNDI3OCM2ODQzOTE5IzIwMDQ4Mzk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxNDI3OCM2ODQzOTE5IzIwMDQ4Mzk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/syndax-announces-participation-at-the-stifel-2025-virtual-targeted-oncology-forum\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Syndax Announces Participation at the Stifel 2025 Virtual Targeted Oncology Forum\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Syndax Announces Participation at the Stifel 2025 Virtual Targeted Oncology Forum - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/syndax-announces-participation-at-the-stifel-2025-virtual-targeted-oncology-forum\/","og_locale":"en_US","og_type":"article","og_title":"Syndax Announces Participation at the Stifel 2025 Virtual Targeted Oncology Forum - Market Newsdesk","og_description":"NEW YORK, April 02, 2025 (GLOBE NEWSWIRE) &#8212; Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, as well as members of the Syndax management team, will participate in a fireside chat at the Stifel 2025 Virtual Targeted Oncology Forum on Wednesday, April 9, 2025, at 10:30 a.m. ET. A live webcast of the fireside chat will be available in the Investor section of the Company&#8217;s website at www.syndax.com, where a replay will also be available for a limited time. About Syndax Syndax Pharmaceuticals\u00a0is a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company&#8217;s pipeline include Revuforj\u00ae (revumenib), &hellip; Continue reading \"Syndax Announces Participation at the Stifel 2025 Virtual Targeted Oncology Forum\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/syndax-announces-participation-at-the-stifel-2025-virtual-targeted-oncology-forum\/","og_site_name":"Market Newsdesk","article_published_time":"2025-04-02T12:02:07+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNDI3OCM2ODQzOTE5IzIwMDQ4Mzk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/syndax-announces-participation-at-the-stifel-2025-virtual-targeted-oncology-forum\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/syndax-announces-participation-at-the-stifel-2025-virtual-targeted-oncology-forum\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Syndax Announces Participation at the Stifel 2025 Virtual Targeted Oncology Forum","datePublished":"2025-04-02T12:02:07+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/syndax-announces-participation-at-the-stifel-2025-virtual-targeted-oncology-forum\/"},"wordCount":204,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/syndax-announces-participation-at-the-stifel-2025-virtual-targeted-oncology-forum\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNDI3OCM2ODQzOTE5IzIwMDQ4Mzk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/syndax-announces-participation-at-the-stifel-2025-virtual-targeted-oncology-forum\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/syndax-announces-participation-at-the-stifel-2025-virtual-targeted-oncology-forum\/","name":"Syndax Announces Participation at the Stifel 2025 Virtual Targeted Oncology Forum - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/syndax-announces-participation-at-the-stifel-2025-virtual-targeted-oncology-forum\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/syndax-announces-participation-at-the-stifel-2025-virtual-targeted-oncology-forum\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNDI3OCM2ODQzOTE5IzIwMDQ4Mzk=","datePublished":"2025-04-02T12:02:07+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/syndax-announces-participation-at-the-stifel-2025-virtual-targeted-oncology-forum\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/syndax-announces-participation-at-the-stifel-2025-virtual-targeted-oncology-forum\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/syndax-announces-participation-at-the-stifel-2025-virtual-targeted-oncology-forum\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNDI3OCM2ODQzOTE5IzIwMDQ4Mzk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNDI3OCM2ODQzOTE5IzIwMDQ4Mzk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/syndax-announces-participation-at-the-stifel-2025-virtual-targeted-oncology-forum\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Syndax Announces Participation at the Stifel 2025 Virtual Targeted Oncology Forum"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/832835","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=832835"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/832835\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=832835"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=832835"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=832835"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}